Want to Collect a High Dividend Every Month? Invest in These 3 Stocks

The article highlights three dividend stocks—AbbVie, Medtronic, and Enbridge—with yields of 3.3%, 3.6%, and 5.2%, respectively, all presented as sustainable and backed by strong cash flow. AbbVie generated $17.8 billion in free cash flow versus $11.7 billion in dividends, Medtronic produced $5.4 billion in trailing-12-month free cash flow versus $3.6 billion in dividend payouts, and Enbridge's 2025 distributable cash flow rose 4% to C$12.5 billion. The piece is broadly supportive of these income names but is mostly investor commentary rather than new market-moving information.

Analysis

The setup is less about “income stocks” than about a three-way barbell on capital discipline: a healthcare royalty stream, a device franchise with steadier mid-single-digit growth, and a toll-road energy asset whose cash flow is increasingly insulated from spot prices. The non-obvious read-through is that lower-rate expectations do not just support yield names mechanically; they also reduce the relative appeal of cash and short-duration Treasuries, which can extend demand for high-quality dividend equities even after a strong run. That said, the market is already rewarding perceived safety, so incremental upside likely comes more from multiple resilience than from yield compression.

The biggest second-order winner is not the three names themselves but adjacent peers with similar payout profiles and cleaner growth visibility. If investors rotate into this “safe yield” bucket, large-cap healthcare with dividend support should outperform lower-quality high-yield sectors where payout coverage is weaker and refinancing sensitivity is higher. In energy, the key nuance is that the dividend story is increasingly a function of contract structure and throughput durability rather than commodity beta; that makes the best-risked exposure the midstream complex, but also raises the odds that yield investors underappreciate how much of the upside is already priced in.

Catalyst risk is asymmetrical over the next 1-3 quarters: any disappointment in drug uptake, medical device procedure volumes, or regulatory pressure on pipeline expansion could quickly narrow the “safe” premium. The consensus seems to be treating these as near-bond substitutes, but that misses the equity duration embedded in each business: healthcare faces patent and reimbursement cliffs, while midstream faces refinancing and volume concentration risk if capital markets tighten. The dividend thesis is strongest if earnings growth stays low-to-mid single digit; if growth decelerates, these can become crowded yield traps despite apparently healthy coverage.

For trading, the better expression is a relative-value basket rather than outright longs: long ABBV/MDT versus high-yield REITs or consumer staples with weaker coverage, to capture quality yield without taking as much rate sensitivity. ENB is best played on pullbacks after the recent rerating, with a 6-12 month horizon and disciplined stops if broader energy rolls over. If yields back up materially, these names likely underperform defensives with less cash-flow cyclicality, so hedge with rate-sensitive shorts rather than index exposure.

Key Decisions for Investors

• Long ABBV vs. high-yield defensives with weaker payout coverage over a 3-6 month horizon; target outperformance if the market continues favoring quality income, but trim if dividend yield spreads compress sharply.
• Add MDT on weakness into post-earnings volatility for a 6-12 month hold; the cleaner risk/reward is procedure-volume normalization plus recurring capital returns, with downside limited by cash-flow coverage.
• Use ENB as a tactical income position only on pullbacks, not chased strength; 6-12 month upside is still decent, but the yield rerating has already removed part of the discount, so position sizing should be smaller.
• Pair long ABBV / short a lower-quality high-yield equity basket for 1-2 quarters to isolate dividend quality versus headline yield, especially if rates stay volatile.
• If long the group, hedge duration with a short in rate-sensitive yield proxies rather than broad market shorts; this preserves the income thesis while reducing the risk from a backup in Treasury yields.